Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanxi Dayu Biological Functions Co has a current ratio of 0.65. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Shanxi Dayu Biological Functions Co has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
Shanxi Dayu Biological Functions Co (BJSE:920970) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Shanxi Dayu Biological Functions Co Current Ratio Related Terms
Shanxi Dayu Biological Functions Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Dayu Biological Functions Co Current Ratio Chart
BJSE:920970 vs VRTX, REGN, MRNA: Current Ratio Comparison
For the Biotechnology subindustry, Shanxi Dayu Biological Functions Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanxi Dayu Biological Functions Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanxi Dayu Biological Functions Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Shanxi Dayu Biological Functions Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Dayu Biological Functions Co (BJSE:920970) has a Current Ratio of 0.65 as of Jun. 2026. This is 35% below median its historical median of 1.00. Over the past decade, Shanxi Dayu Biological Functions Co's Current Ratio has ranged from 0.53 to 7.81. According to the industry distribution chart, Shanxi Dayu Biological Functions Co ranks #1252 out of 1409 companies in the Biotechnology industry, placing it in the top 88.9%.
Is Shanxi Dayu Biological Functions Co's Current Ratio too high?
Shanxi Dayu Biological Functions Co's current Current Ratio of 0.65 is 35% below median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 7.81. The Biotechnology industry median Current Ratio is 3.89. Shanxi Dayu Biological Functions Co's value of 0.65 is 83.3% below this industry median. Based on the distribution chart, Shanxi Dayu Biological Functions Co ranks #1252 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanxi Dayu Biological Functions Co has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanxi Dayu Biological Functions Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanxi Dayu Biological Functions Co ranks #1252 out of 1409 companies for Current Ratio. This places Shanxi Dayu Biological Functions Co in the lower half of its industry. The industry median Current Ratio is 3.89. Shanxi Dayu Biological Functions Co's value of 0.65 is 83.3% below this benchmark. Historically, Shanxi Dayu Biological Functions Co's own Current Ratio has ranged from 0.53 to 7.81 over the past decade. While the company's 10-year median is 1.00 vs. the industry median of 3.89, Shanxi Dayu Biological Functions Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanxi Dayu Biological Functions Co's current Current Ratio of 0.65 is 83.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanxi Dayu Biological Functions Co's current Current Ratio is 0.65, which is 35% below median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanxi Dayu Biological Functions Co stock overvalued right now?
Based on GuruFocus' analysis, Shanxi Dayu Biological Functions Co (BJSE:920970) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.30, compared to a current price of ¥6.69 — trading 8.4% below its estimated fair value. The current Current Ratio is 0.65, which is 35% below median its 10-year median of 1.00 and 83.3% below the Biotechnology industry median of 3.89. Shanxi Dayu Biological Functions Co's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Shanxi Dayu Biological Functions Co (BJSE:920970), the current Current Ratio is 0.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanxi Dayu Biological Functions Co (BJSE:920970) Overvalued in 2026?
Based on GuruFocus' analysis, Shanxi Dayu Biological Functions Co stock appears to be undervalued.
The current stock price of ¥6.69 is trading 8.4% below its estimated GF Value™ of ¥7.30.
GuruFocus considers Shanxi Dayu Biological Functions Co to be Fairly Valued.
Key valuation signals for BJSE:920970:
Current Ratio: 0.65 (35% below median its 10-year median of 1.00)
GF Value™: ¥7.30 vs. price of ¥6.69 (8.4% below fair value)
Industry Position: 83.3% below the Biotechnology median (#1252 of 1409)
No single metric tells the full story. See the BJSE:920970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanxi Dayu Biological Functions Co Ltd engages in the research and development of bioengineering technology and product application. Its main products are probiotics, enzyme preparations, fermented traditional Chinese medicine, biological preparations, and veterinary preparations.
66GF Score
Get the complete analysis for BJSE:920970
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920970 has been successfully added to your 
